Patents. Law. Pharma.
zach@silbersherlaw.com
Zachary Silbersher is a patent attorney with lead-counsel experience in patent litigation, petitions for inter partes review, prosecution and licensing. Mr. Silbersher also consults frequently with buy-side and sell-side analysts on patent litigations within pharma and high-tech spaces. Selected to "IAM Strategy 300 – The World’s Leading IP Strategists" for several years. Quoted repeatedly in the media on patent issues, including The Wall Street Journal, Reuters, Bloomberg, Vox/Recode, The Boston Globe, Nature Biotechnology, FiercePharma, BioWorld, Law360, Intellectual Asset Management (IAM), The Capital Forum, the Patent Investor, and Best Lawyers among others.
Fordham Law, JD 2002
Columbia University, BS Physics 2006
Tufts University, BA Philosophy 1997
Quoted - Compounding Pharmacies for Weight-Loss Drugs Are Booming. Should You Trust Them?
October 7, 2026, Time Magazine, See Publication
The Future of Genus Patenting Strategies for Antibodies Post-Amgen
July 8, 2026, IPWatchdog, See Publication
Speaker - RBC Investor Call - $ERAS $RVMD Patent Allegation re ERAS-0015
June 25, 2026, RBC
Speaker - RBC Investor Call - Pfizer ($PFE) Tafamidis Patent Case
March 20, 2026, RBC
Speaker - Resurrecting Antibody Genus Protection – Allowed Claims Through CDR-Scanning
March 5, 2026, IPWatchdog Webinar, See Webinar
Speaker - RBC Investor Call - Ascendis ($ASND) / Biomarin ($BMRN) TransCon CNP Patent Case
January 7, 2026, RBC
Quoted - Data shows USPTO treating IPR, PGR discretionary denials differently
July 9, 2025, IAM Media, See Publication
Quoted - New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
March 5, 2025, The Wall Street Journal, See Publication
Quoted - The Broad won the biggest CRISPR patent fight yet, but the rivalry over gene editing is still simmering
April 4, 2022, The Boston Globe, See Publication
The Hudson Institute Memo Draws the Wrong Conclusions From Discrepancies in I-MAK's Data
March 23, 2022, IPWatchdog, See Publication
Quoted - Alnylam sues Moderna and Pfizer over key COVID vaccine ingredient
March 22, 2022, The Boston Globe, See Publication
Quoted — U.S. Backs Waiver of Intellectual Property Protection for Covid-19 Vaccines
May 5, 2021, The Wall Street Journal, See Publication
Quoted — How Much Trouble is Lil Nas X in With the Nike Satan Shoe Lawsuit?
March 30, 2021, Vice, See Publication
Quoted — The key ingredient that could hold back vaccine manufacturing
March 3, 2021, Vox/Recode, See Publication
Quoted — Fed. Circ. Ruling May Reshape Hatch-Waxman Litigation Map
November 17, 2020, Law360 — Intellectual Property, See Publication
Quoted — PTAB Decision May Force Changes For Patent Challenge Groups
October 8, 2020, Bloomberg Law, See Publication
Quoted — Moderna Loses Key Patent Challenge, Puts COVID-19 Vaccine at Risk
July 27, 2020, FDANews, See Publication
Quoted — Moderna loses challenge to Arbutus patent on vaccine technology
July 23, 2020, Reuters, See Publication
Speaker — Cantor Fitzgerald Analyst/Industry Discussion: $AMRN Vascepa Patent Litigation
June 29, 2020, Cantor Fitzgerald, See Video
Quoted — 4 Takeaways As AbbVie Crushes ‘Patent Thicket’ Litigation
June 12, 2020, Law360 - Intellectual Property, See Publication
Cytokinetics, Inc. sells a drug, Myqorzo®, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). The drug’s active ingredient is aficamten, which is a cardiac myosin inhibitor. In 2020, Bristol-Myers Squibb acquired a company that sells one of the only other competing drugs to Myqorzo. Then in May 2026, BMS acquired a patent covering the use of aficamten to treat cardiac hypercontractility. Cytokinetics claims BMS acquired this patent only to stifle Myqorzo’s commercial potential. On August 12, Cyotkinetics filed suit against BMS seeking a judgment that it does not infringe BMS’s aficamten patent. Can Cytokinetics extinguish BMS’s patent threat against Myqorzo?